Loading...
•
May 31, 2022
AngioDynamics Q4 2022 Earnings Report
AngioDynamics reported Q4 2022 results with a net sales increase of 13.2% year over year, driven by Med Tech portfolio performance.
Key Takeaways
AngioDynamics reported a strong fourth quarter in fiscal year 2022, with net sales reaching $87.0 million, a 13.2% increase compared to the prior-year quarter. The growth was primarily driven by the Med Tech portfolio, which saw a 40.0% increase in net sales. The company reported a GAAP loss per share of $0.16 and an adjusted earnings per share of $0.01. AngioDynamics issued fiscal year 2023 guidance, expecting net sales to be in the range of $342 to $348 million and adjusted earnings per share in the range of $0.01 to $0.06.
Net sales increased by 13.2% to $87.0 million compared to the prior-year quarter.
Med Tech net sales increased by 40.0% year-over-year.
Gross margin was 53.4%, a decrease of 170 basis points year over year.
The company expects fiscal year 2023 net sales to be in the range of $342 to $348 million.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The Company expects its fiscal year 2023 net sales to be in the range of $342 to $348 million, gross margin to be approximately 52.5% to 54.5% and adjusted earnings per share in the range of $0.01 to $0.06 as it continues to invest in new product launches to drive future growth.
Positive Outlook
- Net sales to be in the range of $342 to $348 million
- Gross margin to be approximately 52.5% to 54.5%
- Adjusted earnings per share in the range of $0.01 to $0.06
- Continued investment in new product launches
- Drive future growth
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...